Related Experiment Video
Updated: Sep 13, 2025
Isolation of Cancer Stem Cells From Human Prostate Cancer Samples
Published on: March 14, 2014
Revolutionizing cancer care: Bioprinting prostate cancer stem cells for targeted treatments
Jaimina Gharia1, Shriya Pimplaskar1, Akhilesh Prajapati2
1Department of Life Sciences, School of Science, GSFC University, Vadodara 391750, Gujarat, India.
Abstract:
Prostate cancer (PCa), one of the leading causes of cancer-related mortality in men worldwide, presents significant challenges due to its heterogeneity and the presence of cancer stem cells (CSCs), which contribute to therapy resistance and metastasis. Advances in three-dimensional (3D) bioprinting have ushered in a new era of precision medicine by enabling the recreation of complex tumor microenvironments. This review highlights the transformative potential of 3D bioprinting technology in modelling prostate cancer stem cells (PCSCs) to identify therapeutic vulnerabilities and develop targeted treatments. By integrating bioinks with PCSCs and their niche components, 3D bioprinting offers a robust platform to investigate the molecular and cellular mechanisms underlying PCa progression and resistance. Furthermore, it allows high-throughput drug screening, cellular cross talks, facilitating the discovery of novel interventions aimed at eradicating CSCs while preserving healthy tissue. The review also discusses the challenges of scalability, bioink optimization, and clinical translation, alongside emerging technologies such as organ-on-chip systems and bioprinted metastatic models. This review underscores the promise of bioprinting as a disruptive innovation in cancer care, capable of redefining therapeutic approaches and offering hope for better patient outcomes in PCa.
Insights
Three-dimensional (3D) bioprinting advances prostate cancer (PCa) research by modeling cancer stem cells (CSCs) and their microenvironments. This technology aids in discovering new therapies targeting therapy-resistant PCa and improving patient outcomes.
Area of Science:
- Oncology
- Biotechnology
- Regenerative Medicine
Background:
- Prostate cancer (PCa) is a leading cause of male cancer mortality, characterized by heterogeneity and therapy-resistant cancer stem cells (CSCs).
- Traditional models struggle to replicate the complex tumor microenvironment, hindering the development of effective treatments.
- CSCs are implicated in PCa metastasis and resistance to conventional therapies.
Purpose of the Study:
- To review the potential of 3D bioprinting in modeling prostate cancer stem cells (PCSCs) and their niche.
- To explore how 3D bioprinting can facilitate the identification of therapeutic vulnerabilities in PCa.
- To discuss the application of 3D bioprinting for drug screening and understanding cellular interactions in PCa.
Main Methods:
- Integration of bioinks with PCSCs and their niche components within 3D bioprinting platforms.
- Utilizing 3D bioprinted models for investigating molecular and cellular mechanisms of PCa progression and resistance.
- Employing 3D bioprinting for high-throughput drug screening and analysis of cellular crosstalk.
Main Results:
- 3D bioprinting enables the recreation of complex PCSC microenvironments for studying PCa.
- This technology facilitates the discovery of novel therapeutic targets and interventions against CSCs.
- Bioprinted models allow for efficient drug screening and investigation of treatment resistance mechanisms.
Conclusions:
- 3D bioprinting is a transformative technology for precision medicine in prostate cancer.
- It offers a powerful platform for developing targeted therapies against PCSCs and improving treatment efficacy.
- Challenges in scalability and clinical translation remain, but bioprinting holds promise for redefining PCa care.
